Some useful links to MPN information resources, guidelines and detailed research articles are provided below.
COVID-19 – please refer to our COVID-19 specific page.
Latest information from ASH 2021 meeting:
Brief summary of ground breaking findings – Dr Ruben Mesa, courtesy of MPN Advocacy and Education International
2020 MPN Patient symposium videos
Presentations by distinguished clinical research physicians and scientists from the world’s leading MPN centres – courtesy Cancer Research and Treatment fund.
2021 International MPN patient conference videos
Presentations and videos for MPN patients from the world’s leading MPN experts – courtesy MPN Education Foundation
- US National Comprehensive Cancer Network (NCCN) Guidelines for Patients: Myeloproliferative Neoplasms 2019
- The 2016 WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: document summary and in-depth discussion
- The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations – 2017
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
- Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms – 2020
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
- Insight for General Practitioners into the classification and clinical approach to diagnosis of MPNs, Australian Journal of General Practice, 2021.
Essential thrombocythaemia (ET) specific information
- Essential thrombocythemia treatment information 2018
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management, USA
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet, 2021
- Updates in the management of polycythemia vera and essential thrombocythemia – USA, August 2019
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Polycythaemia Vera (PV) specific information
- Polycythemia treatment information 2018
- A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline 2019
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management, USA
- Updates in the management of polycythemia vera and essential thrombocythemia -USA, August 2019
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis – A British Society for Haematology Guideline 2018
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Myelofibrosis (MF) specific information
- Primary myelofibrosis: 2021 update on diagnosis, risk stratification and management
- Myelofibrosis in 2019: moving beyond JAK2 inhibition
- Standard care and investigational drugs in the treatment of myelofibrosis, 2019 article
- Prefibrotic Myelofibrosis treatment information 2018
- Myelofibrosis treatment information 2018
- Myelofibrosis Stem Cell Transplant (SCT) Timing Tool
- Survival following allogeneic transplant in patients with myelofibrosis
- FACT SHEETS are provided on all the main treatments available for Australian MPN patients.
- Articles on MPN treatment – this includes comparisons of interferon and hydroxyurea.
- Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood 2019
- Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
- Genetics Home Reference – Your Guide to Understanding Genetic Conditions
- ET https://ghr.nlm.nih.gov/condition/essential-thrombocythemia
- PV https://ghr.nlm.nih.gov/condition/polycythemia-vera#resources
- MF https://ghr.nlm.nih.gov/condition/primary-myelofibrosis
Links to information on various genetic mutations
- JAK2 https://ghr.nlm.nih.gov/gene/JAK2
- CALR https://ghr.nlm.nih.gov/gene/CALR
- MPL https://ghr.nlm.nih.gov/gene/MPL#resources
- TET2 https://ghr.nlm.nih.gov/gene/TET2#conditions